Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics enrols 250 for grass pollen allergy trial

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients.
Allergy Therapeutics enrols 250 for grass pollen allergy trial
Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has enrolled 250 patients into a Phase IIb study in the US for a new injectable treatment for grass pollen sufferers.

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients with headline data expected at the end of the first half of 2016. The results of that should lead on to a US Phase III study.

Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks, avoiding the continuous administration required by conventional subcutaneous injectable treatments.

For the first time, the dosing study will use two mobile environmental exposure chambers.

Based in Cincinnati and in New Jersey Shore, the chambers are inflatable laboratories that enable subjects to be exposed to a constant concentration of pollen for periods of three hours over four consecutive days. These labs will allow the study to be conducted outside of the grass pollen season.

Tim Higenbottam, Allergy‘s R&D director said the trial was on schedule and would prepare the ground for entry into the high value US market.

“GrassMATAMPL has the potential to become the best in class ultra-short course SCIT [injectable] in the US market”

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Related Articles

shutterstock_327930536.jpg
May 19 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...
biotech_564b2dac17b4d.jpg
November 17 2015
Biotech Summit Therapeutics (LON:SUMM is edging closer to a huge 'inflection point', which could potentially transform its fortunes.
inhaler.jpg
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.